You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 33 Blood-based tumor mutation burden (bTMB) predicts response to immune checkpoint blockade-based combination therapy (ICBC) in advanced non-small cell lung cancer (NSCLC): a real-world (RW) analysis

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
33 Blood-based tumor mutation burden (bTMB) predicts response to immune checkpoint blockade-based combination therapy (ICBC) in advanced non-small cell lung cancer (NSCLC): a real-world (RW) analysis

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023184010
Dec 20235708
Jan 20241601
Feb 20242404
Mar 20246404
Apr 20244205
May 20242004
Jun 20241800
Jul 20241603
Aug 20244804
Sep 20243202
Oct 20244507
Nov 20243808
Dec 20242806
Jan 20254007
Feb 2025808
Mar 20250010
Apr 2025202
May 2025003
Jun 2025103
Total683099